Pesquisar
Brainstorm Cell Therapeutics Inc
BCLIAdicionar à lista de desejos
1.170USD
0.0000.00%
Fechamento 07/02, 13:00（ET）Cotações atrasadas em 15 min
9.26MValor de mercado
PerdaP/L TTM
Mais detalhes de Brainstorm Cell Therapeutics Inc Empresa
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimer’s disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Informações de Brainstorm Cell Therapeutics Inc
Código da empresaBCLI
Nome da EmpresaBrainstorm Cell Therapeutics Inc
Data de listagemMay 28, 2003
CEOMr. Chaim Lebovits
Número de funcionários27
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 28
Endereço1325 Avenue Of Americas
CidadeNEW YORK
Bolsa de valoresUS 'Other OTC' and Grey Market
PaísUnited States of America
Código postal10019
Telefone12014880460
Sitehttps://brainstorm-cell.com/
Código da empresaBCLI
Data de listagemMay 28, 2003
CEOMr. Chaim Lebovits
Executivos da empresa Brainstorm Cell Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+2.07%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+12.18%
Dr. Ibrahim B. (Bob) Dagher, M.D.
Dr. Ibrahim B. (Bob) Dagher, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Prof. Jacob A. Frenkel, Ph.D.
Prof. Jacob A. Frenkel, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Menghisteab (Menghis) Bairu, M.D.
Dr. Menghisteab (Menghis) Bairu, M.D.
Independent Director
Independent Director
--
--
Dr. Anthony John (Tony) Polverino, Ph.D.
Dr. Anthony John (Tony) Polverino, Ph.D.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Uri Yablonka
Mr. Uri Yablonka
Director, Executive Vice President, Chief Business Officer, Secretary
Director, Executive Vice President, Chief Business Officer, Secretary
68.46K
--
Dr. Hartoun Hartounian, Ph.D.
Dr. Hartoun Hartounian, Ph.D.
Executive Vice President, Chief Operating Officer
Executive Vice President, Chief Operating Officer
52.00K
--
Ms. Alla Patlis, CPA
Ms. Alla Patlis, CPA
Interim Chief Financial Officer, Controller
Interim Chief Financial Officer, Controller
44.35K
+2.07%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
Director
Director
44.15K
--
Dr. Irit Arbel, Ph.D.
Dr. Irit Arbel, Ph.D.
Independent Vice Chairman of the Board
Independent Vice Chairman of the Board
41.05K
--
Mr. Nir Naor, CPA
Mr. Nir Naor, CPA
Independent Director
Independent Director
31.47K
+12.18%
Perguntas frequentes
Quem são os cinco principais acionistas de Brainstorm Cell Therapeutics Inc?
Os cinco principais acionistas de Brainstorm Cell Therapeutics Inc são: Mr. Uri Yablonka
Quantas instituições possuem ações da Brainstorm Cell Therapeutics Inc (BCLI)?
Em 2026Q1, 77 instituições possuíam ações da Brainstorm Cell Therapeutics Inc, com valor de mercado aproximado de 400.00, representando 0.01% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -1195352.00.